 EDISON, N.J., Sept. 29, 2021 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, a clinical stage biopharmaceutical company focused on Artificial Intelligence AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis NASH and liver disease, today announced results from a Drug-Drug Interaction DDI study with its lead drug candidate, CRV431. 